ASX News

Telix and Kanazawa University Commence Japanese Clinical Study for Prostate Cancer Imaging

Melbourne (Australia) – 14th December 2020. Telix announces its subsidiary, Telix Pharmaceuticals Japan KK, has entered a clinical study collaboration with Kanazawa University (Japan) for the conduct of a Phase I trial of its prostate cancer imaging product.

Telix is pleased to announce its subsidiary, Telix Pharmaceuticals Japan KK has entered a clinical study collaboration with Kanazawa University (Japan) for the conduct of a Phase I trial of  TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the imaging of prostate cancer using Positron Emission Tomography (PET).

The Phase I trial, which will enroll 10 patients with advanced prostate cancer, will be the first clinical trial involving the use of gallium-based PSMA imaging in Japan. Telix has developed TLX591-CDx as a next-generation PET imaging agent that targets prostate-specific membrane antigen (PSMA), which is expressed on the surface of prostate cancer cells. PSMA imaging has emerged as a new standard of care in prostate cancer imaging globally and is already included in clinical practice guidelines in the United States and Europe.

Dr. Shintaro Nishimura, President of Telix Japan, stated “It is a great pleasure to work with Kanazawa University, which is the oldest Department of Nuclear Medicine in Japan. Through this collaboration, we take a first critical step toward providing PSMA imaging to Japanese men with prostate cancer. The annual incidence of prostate cancer in Japan is 70,000 patients with this figure expected to rise over coming years. As such, there is an urgent need to deliver this break-through imaging modality to Japanese patients without delay. We wish to thank Kanazawa University’s Departments of Nuclear Medicine and Urology, the Innovative Clinical Research Center (iCREK), and the Kanazawa Advanced Medical Center (KadMedic) for their support in bringing this important clinical study to realisation.”

Prof. Seigo Kinuya, Professor of Nuclear Medicine at the Kanazawa University Hospital, Department of Nuclear Medicine, Chair of the Japanese Society of Nuclear Medicine, and Chair of the National Conference for Nuclear Medicine Theranostics, added, “The Third-Term Comprehensive 10-year Strategy for Cancer Control, a nationwide initiative advocating the promotion of radiation therapy, has been in place since 2004. In order to deliver on this initiative, concrete development of new diagnostic and therapeutic agents in Japan is essential. Our collaboration with Telix Japan and this first clinical trial of 68Ga-PSMA-11 prostate imaging in Japan are important milestones in the progress of Japanese nuclear medicine. We look forward to providing new diagnostics to patients in Japan as early as possible in collaboration with Telix.”

To read the full media release please click here.

More Articles

ASX News

First U.S. Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 25th January 2021. Telix Pharmaceuticals announces the first U.S. patients have been dosed...

Corporate Spotlight

Telix Pharmaceuticals Appoints Danielle Meyrick MD as CMO, Asia-Pacific

22nd January 2021 – Corporate Spotlight | Telix Pharmaceuticals welcomes Dr Danielle Meyrick as Chief Medical Officer, Asia Pacific

Corporate Spotlight

ARTMS and Telix Pharmaceuticals Announce Successful Production of 68Ga PSMA-11 with Cyclotron Produced 68Ga from a Solid Target

Burnaby, Canada and Indianapolis, USA, January 12, 2021 – ARTMS Inc. and Telix announce successful production of Telix’s prostate cancer...

ASX News

Telix Pharmaceuticals Files New Drug Submission with Health Canada for Prostate Cancer Imaging Product

Melbourne (Australia) and Indianapolis, IN (USA) – 16th December 2020. Telix has filed a New Drug Submission (NDS) with Health Canada...

ASX News

Telix Pharmaceuticals and Mauna Kea Technologies Launch Urologic Oncology Alliance

Melbourne (Australia) – 16th December 2020. Telix Pharmaceuticals announces collaboration with Mauna Kea Technologies to develop advanced image-guided surgical technologies in the field...

ASX News

Telix and Kanazawa University Commence Japanese Clinical Study for Prostate Cancer Imaging

Melbourne (Australia) – 14th December 2020. Telix announces its subsidiary, Telix Pharmaceuticals Japan KK, has entered a clinical study collaboration...

ASX News

Telix Completes IP Agreement with the University of Southampton (UK) Granting Exclusive Access to TRALA Clinical Trial Data

Melbourne (Australia) – 14th December 2020. Telix Pharmaceuticals Limited announces today that its wholly-owned subsidiary TheraPharm GmbH has completed an...

ASX News

Telix Granted TGA Priority Review for Prostate Cancer Imaging

Melbourne (Australia) – 7th December 2020. Telix has been granted Priority Review status for TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the...

ASX News

Telix and DuChemBio Announce Korean Partnership for Advanced Prostate Cancer Imaging

Melbourne (Australia) and Seoul (South Korea) – 3rd December 2020. Telix Pharmaceuticals announces it has entered into a licensing and partnership...

ASX News

Telix Receives Approval for First-In-Human Study of Next Generation Prostate Cancer Therapy Product

Melbourne (Australia) – 2nd December 2020. Telix has been granted HREC approval and received CTN clearance by the TGA to...

ASX News

Investor Briefing – TheraPharm GmbH Acquisition

Melbourne (Australia) – 1st December 2020. Telix Pharmaceuticals Provides Investor Briefing: TheraPharm GmbH Acquisition

ASX News

Telix Pharmaceuticals Limited Acquires TheraPharm GmbH

Melbourne (Australia) and Baar (Switzerland) –  30th November 2020. Telix announces it has entered into an agreement with Scintec Diagnostics...

ASX News

Telix New Drug Application for Prostate Cancer Imaging Product Accepted by US FDA

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 24th November 2020. Telix Pharmaceuticals announces New Drug Application (NDA) for TLX591-CDx (Kit...